NCT02992210View on ClinicalTrials.gov

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2029

Conditions

Solid Tumor

Interventions

GENETIC

4SCAR-GD2

GD2-specific 4th Generation CART

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors

lead

Shenzhen Geno-Immune Medical Institute

OTHER